Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group..

Arch Dermatol. 2003 Jun;139(6):719-27.

PMID:
12810502
3.

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN; Alefacept Clinical Study Group..

J Am Acad Dermatol. 2002 Dec;47(6):821-33.

PMID:
12451365
5.

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

Ellis CN, Krueger GG; Alefacept Clinical Study Group..

N Engl J Med. 2001 Jul 26;345(4):248-55.

6.

An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.

Ortonne JP, Khemis A, Koo JY, Choi J.

J Eur Acad Dermatol Venereol. 2005 Sep;19(5):556-63.

PMID:
16164708
7.
8.

Targeting T-cell subsets to achieve remission.

Christophers E.

J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:6-11.

PMID:
12795769
9.

Alefacept: a novel biologic in the treatment of psoriasis.

Liu CM, McKenna JK, Krueger GG.

Drugs Today (Barc). 2004 Dec;40(12):961-74.

PMID:
15645008
10.

Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.

Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A.

Int J Dermatol. 2003 Mar;42(3):224-30.

11.

Remittive effects of intramuscular alefacept in psoriasis.

Gordon KB, Langley RG.

J Drugs Dermatol. 2003 Dec;2(6):624-8.

PMID:
14711140
12.

Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.

Huang PH, Liao YH, Wei CC, Tseng YH, Ho JC, Tsai TF.

J Eur Acad Dermatol Venereol. 2008 Aug;22(8):923-30. doi: 10.1111/j.1468-3083.2007.02575.x.

PMID:
18312328
13.

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group..

Br J Dermatol. 2005 Jun;152(6):1304-12.

PMID:
15948997
14.

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.

Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A; Alefacept Clinical Study Group..

Arch Dermatol. 2003 Dec;139(12):1563-70.

PMID:
14676071
15.

The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.

Cafardi JA, Cantrell W, Wang W, Elmets CA, Elewski BE.

Skinmed. 2008 Mar-Apr;7(2):67-72.

PMID:
18327010
17.

Development and use of alefacept to treat psoriasis.

Krueger GG, Callis KP.

J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S87-97. Review.

PMID:
12894131
18.

An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.

Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M.

J Am Acad Dermatol. 2005 Jul;53(1):73-5.

PMID:
15965424
19.
20.

Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.

Bovenschen HJ, Gerritsen WJ, van Rens DW, Seyger MM, de Jong EM, van de Kerkhof PC.

Arch Dermatol Res. 2007 Feb;298(9):457-63.

PMID:
17136563
Items per page

Supplemental Content

Support Center